Promises and challenges of adoptive T-cell therapies for solid tumours
Brenton, J. D.
Curbishley, S. M.
Dustin, M. L.
Miller, M. L.
Seymour, L. W.
Van Loo, P.
Church, D. N.
Wedge, David C
Ahmed, A. A.
AffiliationOvarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
MetadataShow full item record
AbstractCancer is a leading cause of death worldwide and, despite new targeted therapies and immunotherapies, many patients with advanced-stage- or high-risk cancers still die, owing to metastatic disease. Adoptive T-cell therapy, involving the autologous or allogeneic transplant of tumour-infiltrating lymphocytes or genetically modified T cells expressing novel T-cell receptors or chimeric antigen receptors, has shown promise in the treatment of cancer patients, leading to durable responses and, in some cases, cure. Technological advances in genomics, computational biology, immunology and cell manufacturing have brought the aspiration of individualised therapies for cancer patients closer to reality. This new era of cell-based individualised therapeutics challenges the traditional standards of therapeutic interventions and provides opportunities for a paradigm shift in our approach to cancer therapy. Invited speakers at a 2020 symposium discussed three areas-cancer genomics, cancer immunology and cell-therapy manufacturing-that are essential to the effective translation of T-cell therapies in the treatment of solid malignancies. Key advances have been made in understanding genetic intratumour heterogeneity, and strategies to accurately identify neoantigens, overcome T-cell exhaustion and circumvent tumour immunosuppression after cell-therapy infusion are being developed. Advances are being made in cell-manufacturing approaches that have the potential to establish cell-therapies as credible therapeutic options. T-cell therapies face many challenges but hold great promise for improving clinical outcomes for patients with solid tumours.
CitationMorotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021.
JournalBritish Journal of Cancer
- Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
- Authors: Zhang E, Gu J, Xu H
- Issue date: 2018 Jan 12
- An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
- Authors: Ott PA, Dotti G, Yee C, Goff SL
- Issue date: 2019 Jan
- Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
- Authors: Kosti P, Maher J, Arnold JN
- Issue date: 2018
- CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
- Authors: Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM
- Issue date: 2018 Oct 9
- CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
- Authors: Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM
- Issue date: 2018